Enabling Personalized Medicine

FluoroFluoroFluoroPharmaPharmaPharmao

Please see disclaimers on the QualityStocks website http://disclaimer.qualitystocks.net

Info@FluoroPharma.comwww.FluoroPharma.com

FluoroPharma, Inc.

500 Boylston Street, Suite 1600Boston, MA 02116

Fax: (617) 482-3337

Contact Company

Phone: (617) 456-0366

Editor@QualityStocks.netwww.QualityStocks.net

QualityStocks

3370 N. Hayden Rd.Suite 123-591Scottsdale, AZ 85251

Phone: (480) 374-1336

Contact QualityStocks

1

FluoroPharma Medical, Inc. (FPMI) is a biopharmaceutical company focused on discovering and developing patented Positron Emission Tomography (PET) imaging products to improve patient management by evaluating cardiac disease at the cellular and molecular levels. The company is currently advancing two products in clinical trials to fulfill critical unmet medical needs. The agents will provide clinicians important tools for detecting and as-sessing pathology before critical manifestations of disease.

The company’s proprietary molecules labeled with the radioactive isotope of fluorine combined with PET scanning provide non-invasive, highly specific and efficient assessment of heart metabolism and physiology. FluoroPharma’s cardiovascular program addresses the largest segment of the nuclear medicine market.

Molecular imaging fulfills numerous unmet needs in diagnosis by enabling visualization, characterization and mea-surement of biological processes at the molecular and cellular level. Unlike traditional imaging modalities – MRI, CT, and Ultrasound – that reveal the anatomical abnormalities and cause for disease, PET provides insight into physiol-ogy and can detect disease before anatomical manifestation is identified. According to GAI, the market for molecular imaging agents currently exceeds $1.7 billion annually and promises rapid growth for the foreseeable future.

FluoroPharma’s comprehensive technology platform was developed by scientists at the Massachusetts General Hos-pital. To date, the company has been issued four US patents and has seven applications pending in addition to strong international protection. With a solid and experienced management team in place and the necessary resources to ad-vance clinical development, FluoroPharma is well positioned to capitalize on its superior imaging technology.

Key Investment Highlights •ClinicalTrialsConfirmedTechnologiesareSafeandareNowEstablishingtheirEfficacy

•IntellectualPropertyinPlacetoProtectProprietaryInnovationsAroundtheWorld

•CashOnHandtoAccelerateBusinessStrategy

•TechnologyTargetsMultiple,MultimillionDollarHealthcareMarketswithStrong/UnmetMedicalNeeds

Enabling Personalized Medicine

FluoroFluoroFluoroPharmaPharmaPharmao

Products

CardioPET (Completed Phase I)

CardioPET is a novel metabolic cardiac PET imaging agent that allows assessment of acute and chronic coronary artery disease while patients are at rest. The imaging agent may be an accurate alternative to standard treadmill stress-testing which could be especially valuable in patients who are unable to exercise.

The CardioPET phase I trial achieved all safety endpoints with no adverse events or clinically significant changes noted in follow-up clinical and laboratory testing. The agent had rapid extraction from blood with sustained levels in myocardium. CardioPETperformedwellinbothhealthyvolunteersandpatientswithCAD.

BFPET (Completed Phase I)

BFPETisanovelcardiovascularbloodflowimagingagentthatconcentratesinhealthymyocardialcells.Theagentisusedto detect presumptive CAD in combinationwith stress testing and enables improved detection of CAD ofmulti-vesseldisease. According to Frost & Sullivan, more than 10 million Americans undergo myocardial perfusion imaging each year.

TheBFPETphase I trial achieved all safety endpointswithno adverse eventsor clinically significant changesnoted infollow-up clinical and laboratory testing. The agent demonstrated a favorable dosimetry and pharmacokinetics profile and iswelltolerated.Biodistributionresultsindicatedfastbloodclearance,rapidandstablemyocardialuptakeandhighheartto background ratios.

VasoPET (Preclinical)

VasoPET is the only PET agent known to selectively target inflamed or “vulnerable” atheromatous plaque. With this agent, physicians could be able to identify coronary artery plaque – an unhealthy though typical accumulation of cell debris, in-cluding cholesterol, calcium mineral and tissue within the arterial walls especially when inflamed – an ominous condition and precursor to myocardial infarction and possibly death.

FluoroPharma’s third important agent in the cardiovascular disease market, VasoPET could represent the first PET cardiac product to reliably image inflamed plaque, providing true diagnostic sensitivity and specificity for this dangerous and often fatal cardiac disease condition.

AZPET (Discovery)

Multiple biomarkers for imaging and treatment of Alzheimer’s disease.

2

Enabling Personalized Medicine

FluoroFluoroFluoroPharmaPharmaPharmao

Market Opportunity

BFPET Market Opportunity

ThedemandforBFPETisanticipatedtobedrivenbyitsuseasabloodflowimagingagenttoidentify ischemicandin-farctedtissueinpatientswithchronicCAD;andincombinationwithametabolicimagingagentinpatientswithacuteCADthat are undergoing CVA. According to Frost & Sullivan, there were 11.2 million cardiovascular related SPECT procedures performed in 2007 with an annual growth rate of 6.2%.

ItisbelievedthatBFPETcurrentlyrepresentsoneoftwoagentsintheregulatoryprocessforcommercializationforthePETmarket.ThecompanybelievesthatfiveyearsfollowingcommercializationthatBFPETcouldachieve25%marketshareofthemolecular imaging market and that FluoroPharma has the potential to obtain 60% share of the valuable cardiovascular PET market.WithinthePETmarketforCVA,FluoroPharmabelievesthatBFPETmaybeusedinitially10%ofthetime.BFPETcouldeventually capture 40% of the blood flow component for the CVA market opportunity.

CardioPET Market Opportunity

Itisestimatedthat1.75millionpatientswithchronicformsofCADundergopharmacologicstress-testingduetoaninabilitytoperformexercisestress-testingeachyearintheU.S.Becausetheredoesn’tappeartobeanyproductcurrentlyonthemarket that allows for at-rest assessment of this population, CardioPET is poised to be readily adopted by the cardiology community for the assessment of this patient pool. FluoroPharma anticipates that PET could achieve a 30% share of the overallcardiovascularimagingmarket,andthatCardioPETcouldachievea25%shareofthecardiovascularPETmarket.

WithintheCVAsegmentoftheCADmarket,FluoroPharmabelievesCardioPETpossessesmanysignificantadvantagesandcould be the ideal agent for the detection of discordances, and the identification of jeopardized but viable myocardium in the350,000patientswithpresumptivehibernatingorstunnedmyocardium.CardioPETcouldalsorepresentabestinclassmetabolic imagingagenttoreachthePETcardiacmarket.FluoroPharmaestimatesthat in2015,PETmaycapture35%market share of the overall valuable imaging market for this indication upon commercialization and that CardioPET could capture 20% of the PET market. Eventually, FluoroPharma products may account for 60% of the cardiovascular PET market.

VasoPET Market Opportunity

Preliminary estimates for the VasoPET market are a direct function of the 30% of patients that have undergone con-ventional stress-testing that are diagnosed with chronic forms of ischemia. FluoroPharma believes there is a significant need to identify vulnerable plaque from stable forms of plaque in this patient population. FluoroPharma estimates that afterVasoPET’sapproval, thePETmarketcouldachievea35%shareof thecardiovascular imagingmarketand thatVasoPETcouldcapture35%ofthevaluablecardiovascularPETmarket.Eventually,FluoroPharmabelievesthatPETmaybeusedtoevaluate50%ofthepatientpopulationandthatVasoPET‘speakmarketpenetrationmayapproach50%.

3

Enabling Personalized Medicine

FluoroFluoroFluoroPharmaPharmaPharmao

4

Management

Thijs SpoorDirector,CEO&President

Mr.SpoorholdsaNuclearPharmacydegreefromtheUniversityofTorontoaswellasanM.B.A.fromColumbiaUniversitywithconcentrationsinfinanceandaccounting.Mr.SpoorhasbeenaguestlectureratColumbiaBusi-nessSchool,KingsCollegeinLondonandtheUniversityofNewcastleinAustraliaandhaspresentedatmedicalgrand rounds and psychiatric grand rounds at various hospitals on the role of brain imaging.

PriortojoiningFluoroPharma,Mr.SpoorwastheCFOofSunstoneBioSciencesandalsoworkedasastrategyconsultantatOliverWyman,focusingonhelpingpharmaceuticalandmedicaldevicecompaniesevaluatetheirglobal revenue potential given the complex interplay of regulatory approvals, the reimbursement environment, as well as the impact of physician preference within constantly evolving standards of care. He further specialized on the implications of healthcare reform on new product approval and health insurance reform.

Mr.SpoorhasalsobeenanequityresearchanalystatJ.P.MorganandCreditSuissecoveringtheBiotechnologyandMedicalDeviceindustries.Mr.Spoorworkedinthepharmaceuticalindustryspendingmorethan10yearswithAmersham/GEHealthcarewhereheworkedin7countriesinavarietyofrolesincludingsettingupGMPfacilitiesmeetingISO9001standards,accountabilityfortheentirenuclearcardiologyportfolioandmostrecentlyastheDirectorofNewProductOpportunitiesleadingthePETstrategicplan.

Boyan Goumnerov, MDCOO&VicePresidentClinicalTrials

PriortohisappointmentwithFluoroPharma,Dr.Goumnerovhasheldexecutivepositionsinthehealthcareandbiomedicalresearchfields;mostrecentofwhicharePresidentofVasoStent,Inc.andmanagingdirectorofCar-dioVas Inc., start-up medical device companies targeting the field of intravascular cardiac imaging and therapy. Hisacademicbackground includes researchwithin thedepartmentsofSurgeryandMolecularBiologyat theMassachusettsGeneralHospital(MGH)andTheShrinersBurnHospitalforChildren,Boston,whereheheldaca-demic appointments with Harvard Medical School.

Dr.GoumnerovalsodidextensiveworkwithintheDepartmentofPathology/NeuropathologyatChildren’sHos-pitalBoston,indevelopingimageanalysisprotocolsforevaluationofneuromusculardiseasesbeforemovingtoMGH.Heisco-authorofnumerousscientificpublications.Dr.GoumnerovobtainedhisM.D.fromtheMedicalUniversityofSofia,Bulgaria,andworkedasaclinicianpriortorelocatingtotheUS.

Enabling Personalized Medicine

FluoroFluoroFluoroPharmaPharmaPharmao

5

Management (continued...)

David R. Elmaleh, PhDChairman,DirectorandChiefScientificAdvisor

Dr.Elmaleh,thescientificfounderofFluoroPharmaInc.,isanAssociateProfessoratHarvardMedicalSchoolandtheDirectorofContrastMediaChemistryattheMassachusettsGeneralHospital(“MGH”).Heisaninventorofthreedrugsthatareinuseorinlatestageclinicaltrialsincluding:theradiopharmaceuticalpreparationof(2FDG),whichhasbeenusedinoveramillionPETimagingprocedures;Beta-methylmodifiedfattyacid(BMIPP),acommerciallysuccessfulcardiacSPECTagent;andAltropane,whichhascompletedPhaseIIIclinicaltrials.

His recent work has included extensive research on imaging compounds to improve the speed and effectiveness of cardiovascular disease diagnosis which constitutes the technology licensed from MGH to FluoroPharma. He is a co-author on over 120 publications and an inventor of over 40 issued and pending patents in a range of disciplines, includingmolecularimagingandpharmaceuticals.Dr.ElmalehisarecipientofnumerousNIHandDOEawards,andhasparticipatedasareviewerfortheNationalInstituteofHealth(NIH).HeistheScientificFounderofBiostream(nowMolecularInsightPharmaceuticals)andseveralotherstart-ups.HeholdsaBScinPhysicsandChemistry,andanMSandPhDinChemistryfromtheHebrewUniversityofJerusalem.

Peter Conti, MD, PhDDirector,ScientificAdvisoryBoard

Dr.ContiisProfessorofRadiology,BiomedicalEngineeringandPharmacyattheUniversityofSouthernCalifor-nia.HehasbeentheDirectoroftheUSCPETImagingScienceCentersinceitsinceptionin1991.HeservedasthePresidentoftheSocietyofNuclearMedicineandisamajorcontributortothedevelopmentofclinicalPETandmolecularimaging.OneofDr.Conti’smajorresearchinterestsisinthedevelopmentofmolecularimagingagentsforthediagnosisandmonitoringofcancermetabolismandcellproliferation.Dr.ContiisBoardcertifiedinbothDiagnosticRadiologyandNuclearMedicine.HereceivedbothhisMDandPhDdegreesfromCornellUniversity.

Walter WitoshkinDirector,BoardofDirectors

Walter Witoshkin is an accomplished executive with 40-years’ experience in the pharmaceutical, healthcare and biomedical industries. Mr. Witoshkin specialized in alternative sourcing for manufacturing and the acquisition of technologiesandproducts.Mr.WitoshkinpreviouslyheldexecutivepositionswithQuantRxBiomedicalCorpora-tion, a medical technology company with leading edge diagnostic and therapeutic technologies. Mr. Witoshkin has previously held executive positions in the healthcare and pharmaceutical industries including senior financial posi-tionsatWyethLabs(AmericanCyanimade),VPBusinessDevelopmentandCFOpositionsatSmithKlineBeecham(now Glaxo SmithKline) and Menley& James Laboratories, Inc. He is a founding partner of the Trident Group, a globalconsultancytothepharmaceuticalindustry.HeisChairmanoftheBoardatQuiqMedsInc.